Arcadia Q1 net loss $4.4M ($2.11/share); Zola volumes +18% YoY

Arcadia Biosciences, Inc.

2026-Q1 EPS reported -$2.11 revenue$1,100,000

Net loss attributable to common stockholders $4.385M (EPS -$2.11) vs net income $2.599M ($1.90 EPS) in Q1 2025.
Zola coconut water unit volume +18% YoY; total revenue $1.1M down 8% due to $193k revenue reserve release in prior year.
SG&A $1.179M, lowest in public company history, down $559k YoY; cash and equivalents $0.954M vs $0.259M at year-end.
January 2026 warrant inducement generated $2.1M gross proceeds but caused $2.877M loss; company continues evaluating strategic alternatives.
Company plans new product launch fall 2026; Zola benefited from price increase at start of year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcadia Biosciences, Inc. reported financial results for first quarter of 2026.

Period: first quarter of 2026
Result: reported results

Exact text from the filing

On May 14, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter of 2026.

View on SEC.gov

Browse all earnings releases →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-223985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.